What Is a Plastic Surgery Rewind
A plastic surgery rewind refers to corrective or revision procedures performed after an initial operation results in complications, asymmetry, or functional impairment. The American Society of Plastic Surgeons (ASPS) reports that revision rhinoplasty and breast implant removal are among the most common rewind requests, with patient inquiries rising as revision-focused clinics expand their marketing. The global market for revision and reconstructive procedures is tracked alongside elective aesthetics by firms such as GlobalData and Statista, which publish annual procedure volumes and spending estimates. Investors monitor companies like Allergan, Mentor Worldwide, and Sientra for regulatory actions and product recalls that drive demand for rewind surgeries. Read more on Forbes
Why Patients Seek a Rewind
Patients pursue a rewind for medical reasons such as capsular contracture, implant rupture, or nerve damage, and for aesthetic reasons including dissatisfaction with scarring or proportion. The ASPS notes that revision rates vary by procedure, with breast augmentation revisions occurring in roughly 10 to 15 percent of cases within a decade, and rhinoplasty revisions often cited at 5 to 10 percent. Companies such as Implantech and Polytech offer specialized implants designed to reduce rewind needs, while regulatory bodies like the FDA track adverse event reports that highlight device-related failures. FDA Medical Device Reporting
Financial and Regulatory Landscape
Revision surgeries cost patients an estimated $5,000 to $15,000 per procedure in the United States, according to data from the American Society of Plastic Surgeons and industry cost surveys. Insurance coverage depends on whether the rewind is deemed medically necessary, with many patients paying out of pocket for aesthetic corrections. Publicly traded companies in the aesthetic device space, including InMode, Alma Lasers, and Cutera, report procedure volumes that correlate with revision demand. The SEC filings of these firms disclose revenue breakdowns by product line, enabling investors to track how regulatory recalls or safety warnings affect sales. SEC Filings for InMode
Regulatory Actions and Product Recalls
The FDA maintains a database of device recalls and safety communications that directly impact revision surgery volumes, with breast implant recalls by Allergan in 2019 linked to a global surge in explant and rewind procedures. The FDA's Manufacturer and User Facility Device Experience (MAUDE) database logs adverse events that inform both clinician decisions and investor risk assessments. Companies that fail to address device-related complications may face litigation costs, as seen in the bankruptcy of Allergan's parent company and subsequent acquisition by AbbVie. Forbes Analysis
Industry Trends and Investor Implications
The revision and rewind segment is growing as a share of total aesthetic procedure revenue, driven by aging primary cohorts and increased awareness of long-term implant risks. Industry analysts at Grand View Research and MarketsandMarkets project compound annual growth rates for revision breast surgery and facial rework procedures in the mid-single-digit percent range through the mid-2020s. Companies with strong